Qualigen Therapeutics QLGN Stock
Qualigen Therapeutics Price Chart
Qualigen Therapeutics QLGN Financial and Trading Overview
| Qualigen Therapeutics stock price | 3.13 USD |
| Previous Close | 1.03 USD |
| Open | 1.09 USD |
| Bid | 1 USD x 3000 |
| Ask | 1.04 USD x 3000 |
| Day's Range | 1.02 - 1.09 USD |
| 52 Week Range | 0.83 - 4.08 USD |
| Volume | 5.41K USD |
| Avg. Volume | 27.2K USD |
| Market Cap | 5.41M USD |
| Beta (5Y Monthly) | 0.124606 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 3635 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 22.5 USD |
QLGN Valuation Measures
| Enterprise Value | 8.54M USD |
| Trailing P/E | N/A |
| Forward P/E | -0.76971227 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 0.89125377 |
| Price/Book (mrq) | 2.6548388 |
| Enterprise Value/Revenue | 1.408 |
| Enterprise Value/EBITDA | -0.54 |
Trading Information
Qualigen Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.124606 |
| 52-Week Change | N/A |
| S&P500 52-Week Change | N/A |
| 52 Week High | 4.08 USD |
| 52 Week Low | 0.83 USD |
| 50-Day Moving Average | 1.03 USD |
| 200-Day Moving Average | 1.2 USD |
QLGN Share Statistics
| Avg. Volume (3 month) | 27.2K USD |
| Avg. Daily Volume (10-Days) | 10.95K USD |
| Shares Outstanding | 5.05M |
| Float | 5.02M |
| Short Ratio | 0.84 |
| % Held by Insiders | 11.55% |
| % Held by Institutions | 2.16% |
| Shares Short | 35.69K |
| Short % of Float | 0.70% |
| Short % of Shares Outstanding | 0.70% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:25 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | June 30, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -288.66% |
| Operating Margin (ttm) | -264.39% |
| Gross Margin | 8.21% |
| EBITDA Margin | -260.95% |
Management Effectiveness
| Return on Assets (ttm) | -50.74% |
| Return on Equity (ttm) | -185.52% |
Income Statement
| Revenue (ttm) | 6.07M USD |
| Revenue Per Share (ttm) | 1.34 USD |
| Quarterly Revenue Growth (yoy) | 13.70% |
| Gross Profit (ttm) | 680.8K USD |
| EBITDA | -15827476 USD |
| Net Income Avi to Common (ttm) | -17507778 USD |
| Diluted EPS (ttm) | -4.04 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 1.34M USD |
| Total Cash Per Share (mrq) | 0.27 USD |
| Total Debt (mrq) | 3.2M USD |
| Total Debt/Equity (mrq) | 96.84 USD |
| Current Ratio (mrq) | 0.572 |
| Book Value Per Share (mrq) | 0.403 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -10982158 USD |
| Levered Free Cash Flow (ttm) | -4421102 USD |
Profile of Qualigen Therapeutics
| Country | United States |
| State | CA |
| City | Carlsbad |
| Address | 2042 Corte Del Nogal |
| ZIP | 92011 |
| Phone | (760) 918-9165 |
| Website | https://www.qualigeninc.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 31 |
Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
Q&A For Qualigen Therapeutics Stock
What is a current QLGN stock price?
Qualigen Therapeutics QLGN stock price today per share is 3.13 USD.
How to purchase Qualigen Therapeutics stock?
You can buy QLGN shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Qualigen Therapeutics?
The stock symbol or ticker of Qualigen Therapeutics is QLGN.
Which industry does the Qualigen Therapeutics company belong to?
The Qualigen Therapeutics industry is Biotechnology.
How many shares does Qualigen Therapeutics have in circulation?
The max supply of Qualigen Therapeutics shares is 736.43K.
What is Qualigen Therapeutics Price to Earnings Ratio (PE Ratio)?
Qualigen Therapeutics PE Ratio is 0.00086107 now.
What was Qualigen Therapeutics earnings per share over the trailing 12 months (TTM)?
Qualigen Therapeutics EPS is 3635 USD over the trailing 12 months.
Which sector does the Qualigen Therapeutics company belong to?
The Qualigen Therapeutics sector is Healthcare.
Qualigen Therapeutics QLGN included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 15587.79 USD — |
-5.82
|
9.14B USD — | 15575.68 USD — | 16128.16 USD — | — - | 9.14B USD — |
| NASDAQ HealthCare IXHC | 869.8 USD — |
-5.51
|
— — | 868.74 USD — | 900.72 USD — | — - | — — |
- {{ link.label }} {{link}}